Clinical

Articles

Branded and unbranded versions of the interchangeable biosimilar to treat patients with diabetes are now available.

Biocon Launches Biosimilar Semglee

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.

Prime Therapeutics Adds the Biosimilar Semglee to Preferred Formulary

Express Scripts will put the first interchangeable biosimilar insulin on its National Preferred Formulary and exclude Lantus, the reference product.

Express Scripts Adds Biosimilar Semglee to Preferred Formulary

Effective Jan. 1 2022, the move brings the price to 2008 levels.

Lilly Lowers List Price of Insulin Lispro

The approval allows for substitution at the pharmacy counter for Lantus, its reference product.

FDA Approves First Interchangeable Biosimilar Insulin

Keytruda gets a full approval in endometrial cancer; while Xeljanz will miss another PDUFDA date.

Merck Vaccine and Other FDA Updates

FDA staff raised safety concerns ahead of the advisory panel hearing.

FDA Panel Hearing on Roxadustat Leads the Week

A longstanding four times per day testing requirement will cease, and patients using inhaled insulin now qualify for continuous glucose monitoring.

CMS Changes Coverage for CGM Devices

Semaglutide injection is a weekly injection for chronic weight management in adults.

FDA clears first chronic weight loss drug in 7 years

The AstraZeneca drug is the first SGLT2 inhibitor approved for chronic kidney disease regardless of whether the patient  has diabetes.

Diabetes and Endocrinology